Cell Therapy

Mesenchymal Stem Cells

Umbilical cord mesenchymal stem cells generally possess self-renewal ability,multi-lineage differentiation potential,and immunomodulatory functions.Based on their unique biological properties,they demonstrate distinctive clinical application prospects by secreting various functional cytokines,particularly in regulating immunity and inflammatory responses,promoting cell and tissue repair.Over the past decade,clinical research on stem cells has been conducted worldwide,involving different organ systems such as the nervous system(e.g.,Parkinson’s disease,Alzheimer’s disease,spinal cord injury),the digestive system(e.g.,cirrhosis,hepatitis),cardiovascular diseases(e.g.,myocardial infarction,ischemic cardiomyopathy),and immune diseases(e.g.,lupus).Research data has demonstrated the safety and clinical efficacy of stem cell products.Currently,ten MSC stem cell drugs have been approved and are available globally.

DC Neoantigen Vaccines

Natural killer cells(NK)in the immune system launch an attack upon discovering cancer cells while summoning dendritic cells(DC)to record their characteristics and relay them to the body’s killer cells(T cells).Cytotoxic T cells possess strong cancer cell-killing capabilities but lack the ability to recognize cancer cells.Dendritic cells are the most potent professional antigen-presenting cells(APC),often referred to as the "sentinels" of the immune system and the initiators of the body's immune response.Therefore, mature dendritic cells can"teach"T cells how to recognize cancer cells.They can also promote the proliferation and differentiation of B cells,participating in humoral immune responses.As a result, the most popular cell immunotherapies today are based on the "anti-cancer" characteristics of these immune cells,such as CAR-T cell immunotherapy,NK cell immunotherapy,and dendritic cell immunotherapy,with dendritic cell immunotherapy targeting specific cancer cells and having virtually no side effects.The most valuable aspect of DC vaccines is their dual ability to eliminate cancer cells and prevent recurrence.Etta has completed the entire process for DC cell isolation,purification,transfection,and culture,and partners have already entered the IND clinical stage.

NK Cell Immunotherapy

NK cell immunotherapy involves expanding autologous or allogeneic NK cells in vitro and then infusing them into cancer patients to kill tumors.NK cell immunotherapy can be divided into two main categories:(1)Autologous NK cell therapy:This involves collecting NK cells from the patient's peripheral blood,expanding and processing them in vitro,and then reinfusing them into the patient.(2)Allogeneic NK cell therapy: In this case,NK cells are sourced from outside the patient,including NK cell lines,healthy donors'NK cells,human embryonic stem cells,and iPSC-derived NK cells.NK cells are an essential lymphocyte subset of the body and the first line of defense in anti-tumor immunity.They have a broad-spectrum tumor-killing effect and are equally sensitive to multi-drug-resistant tumor cells.They specifically kill tumor cells without harming normal cells,rebuild and enhance the patient's overall immune function,and comprehensively recognize,seek out,and kill tumor cells,effectively preventing tumor recurrence and metastasis.They activate the body's immune memory function,providing long-lasting tumor cell killing.NK cells can effectively treat most solid tumors and eliminate tumor cells that are resistant to radiation and chemotherapy or have metastasized.They do not rely on antigen stimulation and can non-specifically directly kill tumor and virus-infected target cells.They can improve the body's immune environment and enhance immune function.Currently,allogeneic NK cell therapy is considered more effective than autologous NK cell therapy for treating tumors,as it addresses the issue of weakened immune system function in patients with no toxic side effects.CAR-NK uses genetic engineering to add a chimeric antibody to NK cells that can recognize tumor cells while simultaneously activating NK cells to kill the tumor cells.Chimeric antigen receptors significantly improve the specificity of NK cell efficacy.This concept is similar to the well-known CAR-T construct.Etta has completed the entire process for NK cell isolation,purification,activation,transfection,and culture,and partners have already entered the IND clinical stage.

Others

Etta offers comprehensive protocol services,including immune/stem cell isolation,purification,culture,and activation,as well as non-viral transfection process development services for DNA,transposons,mRNA,and CRISPR gene editing technologies in immune and stem cells.